- Home
- LARK vs PROK Comparison
LARK vs PROK Comparison
Compare LARK & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LARK | PROK |
|---|---|---|
| Founded | 1885 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 417.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LARK | PROK |
|---|---|---|
| Price | $27.76 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 9.5K | ★ 1.3M |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $64,367,999.00 | $744,000.00 |
| Revenue This Year | N/A | $956.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | ★ 12.95 | N/A |
| 52 Week Low | $20.99 | $0.46 |
| 52 Week High | $29.56 | $7.13 |
Technical Indicators
Market Signals| Indicator | LARK | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 43.72 |
| Support Level | $27.30 | $2.33 |
| Resistance Level | $28.76 | $2.59 |
| Average True Range (ATR) | 0.78 | 0.16 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 5.73 | 26.42 |
Price Performance
Historical ComparisonAbout LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.